
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
Departments of Surgery [M. K. B., K. M., W. O., K. C., M. M., D. J. C., W. E. G.], Pathology and Laboratory Medicine [R. H.], and Medicine [F. B., R. K-H.], Medical University of South Carolina, Charleston, South Carolina 29425
Purpose: The goal of this study was to develop a molecular diagnostic assay to detect circulating breast cancer cells in the peripheral blood for the purpose of staging breast cancer. Our aim was to make available an assay that was not limited by the low concentration of circulating breast cancer cells and the background gene expression that is typically found in peripheral blood.
Experimental Design: In this study, we investigated the ability of two new technologies to significantly enhance the quantification of gene expression in the peripheral blood: enrichment by a novel porous barrier density gradient centrifugation technology; and multimarker real-time reverse transcription-PCR (RT-PCR).
Results: Using fluorescence-labeled breast cancer cells and flow cytometry, we show that processing peripheral blood by porous barrier density gradient centrifugation results in a 300-fold enrichment of breast cancer cells. Real-time RT-PCR analysis confirmed a concomitant reduction in background expression of the CK19 and MUC1 genes after enrichment. In a pilot study, porous barrier density gradient centrifugation and multimarker real-time RT-PCR enabled our laboratory to detect breast cancer-associated gene overexpression in 13 of 20 (65%) stage IV breast cancer patients. Nine of these 14 patients overexpressed three or more markers.
Conclusions: These results confirm the promise of such a molecular diagnostic assay and suggest that additional studies are needed to precisely define the clinical relevance.
This article has been cited by other articles:
![]() |
Y.-H. Uen, C.-Y. Lu, H.-L. Tsai, F.-J. Yu, M.-Y. Huang, T.-L. Cheng, S.-R. Lin, and J.-Y. Wang Persistent Presence of Postoperative Circulating Tumor Cells is a Poor Prognostic Factor for Patients with Stage I-III Colorectal Cancer after Curative Resection Ann. Surg. Oncol., August 1, 2008; 15(8): 2120 - 2128. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Harris, H. Fritsche, R. Mennel, L. Norton, P. Ravdin, S. Taube, M. R. Somerfield, D. F. Hayes, and R. C. Bast Jr American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer J. Clin. Oncol., November 20, 2007; 25(33): 5287 - 5312. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Bagatell, L. Gore, M. J. Egorin, R. Ho, G. Heller, N. Boucher, E. G. Zuhowski, J. A. Whitlock, S. P. Hunger, A. Narendran, et al. Phase I Pharmacokinetic and Pharmacodynamic Study of 17-N-Allylamino-17-Demethoxygeldanamycin in Pediatric Patients with Recurrent or Refractory Solid Tumors: A Pediatric Oncology Experimental Therapeutics Investigators Consortium Study Clin. Cancer Res., March 15, 2007; 13(6): 1783 - 1788. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Lacroix Significance, detection and markers of disseminated breast cancer cells Endocr. Relat. Cancer, December 1, 2006; 13(4): 1033 - 1067. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Flamini, L. Mercatali, O. Nanni, D. Calistri, R. Nunziatini, W. Zoli, P. Rosetti, N. Gardini, A. Lattuneddu, G. M. Verdecchia, et al. Free DNA and Carcinoembryonic Antigen Serum Levels: An Important Combination for Diagnosis of Colorectal Cancer Clin. Cancer Res., December 1, 2006; 12(23): 6985 - 6988. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Mercatali, V. Valenti, D. Calistri, S. Calpona, G. Rosti, S. Folli, M. Gaudio, G. L. Frassineti, D. Amadori, and E. Flamini RT-PCR determination of maspin and mammaglobin B in peripheral blood of healthy donors and breast cancer patients Ann. Onc., March 1, 2006; 17(3): 424 - 428. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. N. Span, F. C.G.J. Sweep, K. Mikhitarian, W. E. Gillanders, D. J. Cole, M. Mitas, and M. Reinholz Mammaglobin as Molecular Marker of Breast Cancer (Micro)Metastases Clin. Cancer Res., October 1, 2005; 11(19): 7043 - 7044. [Full Text] [PDF] |
||||
![]() |
K. Koyanagi, C. Kuo, T. Nakagawa, T. Mori, H. Ueno, A. R. Lorico Jr, H.-J. Wang, E. Hseuh, S. J. O'Day, and D. S.B. Hoon Multimarker Quantitative Real-Time PCR Detection of Circulating Melanoma Cells in Peripheral Blood: Relation to Disease Stage in Melanoma Patients Clin. Chem., June 1, 2005; 51(6): 981 - 988. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Muller, N. Stahmann, S. Riethdorf, T. Rau, T. Zabel, A. Goetz, F. Janicke, and K. Pantel Circulating Tumor Cells in Breast Cancer: Correlation to Bone Marrow Micrometastases, Heterogeneous Response to Systemic Therapy and Low Proliferative Activity Clin. Cancer Res., May 15, 2005; 11(10): 3678 - 3685. [Abstract] [Full Text] [PDF] |
||||
![]() |
A M Gilbey, D Burnett, R E Coleman, and I Holen The detection of circulating breast cancer cells in blood J. Clin. Pathol., September 1, 2004; 57(9): 903 - 911. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |